7th Mar 2024 7:00 am |
RNS |
GSK announces positive Blenrep DREAMM-8 results |
6th Mar 2024 4:00 pm |
RNS |
ViiV LAI vs oral SOC data in adherence-challenged |
5th Mar 2024 5:24 pm |
RNS |
GSK Annual Report 2023 on Form 20-F |
5th Mar 2024 7:00 am |
RNS |
New ViiV LA formulation potential 4-month dosing |
1st Mar 2024 3:00 pm |
RNS |
Total Voting Rights |
1st Mar 2024 12:15 pm |
RNS |
GSK publishes Annual Report 2023 |
29th Feb 2024 7:05 am |
RNS |
Directorate Change |
29th Feb 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
26th Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
26th Feb 2024 7:00 am |
RNS |
GSK announces positive EAGLE-1 headline results |
22nd Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
21st Feb 2024 7:00 am |
RNS |
ViiV LAI superior to orals in adherence-challenged |
20th Feb 2024 9:01 am |
RNS |
Julie Brown - External Appointment |
19th Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
15th Feb 2024 3:32 pm |
RNS |
Director/PDMR Shareholding |
15th Feb 2024 7:00 am |
RNS |
GSK completes acquisition of Aiolos Bio |
13th Feb 2024 4:45 pm |
RNS |
Director/PDMR Shareholding - Replacement |
13th Feb 2024 3:40 pm |
RNS |
Director/PDMR Shareholding |
13th Feb 2024 3:35 pm |
RNS |
Director/PDMR Shareholding |
13th Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
6th Feb 2024 7:10 am |
RNS |
FDA accepts Arexvy filing for adults 50-59 at risk |
6th Feb 2024 7:05 am |
RNS |
Shingrix 18+ at risk China filing review accepted |
6th Feb 2024 7:00 am |
RNS |
GSK presents positive DREAMM-7 phase III data |
1st Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
1st Feb 2024 3:00 pm |
RNS |
Total Voting Rights |
1st Feb 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
31st Jan 2024 7:00 am |
RNS |
Final Results |
29th Jan 2024 7:05 am |
RNS |
EMA accepts Arexvy filing for adults 50-59 at risk |
29th Jan 2024 7:00 am |
RNS |
European Commission authorises Omjjara in the EU |
19th Jan 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
18th Jan 2024 5:00 pm |
RNS |
Holding(s) in Company |
17th Jan 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
17th Jan 2024 7:00 am |
RNS |
GSK completes sale of shares in Haleon plc |
16th Jan 2024 4:40 pm |
RNS |
GSK announces intention to sell shares in Haleon |
16th Jan 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
10th Jan 2024 7:00 am |
RNS |
Nucala approved in China for use in severe asthma |
9th Jan 2024 7:00 am |
RNS |
GSK enters agreement to acquire Aiolos Bio |
2nd Jan 2024 3:00 pm |
RNS |
Total Voting Rights |
21st Dec 2023 3:30 pm |
RNS |
Director/PDMR Shareholding |
20th Dec 2023 4:44 pm |
RNS |
Publication of EMTN Suppl.Prospcts |